Burney CO Vertex Pharmaceuticals Inc Transaction History

Burney CO

$2.39 Billion
Q1 2024

A detailed history of Burney CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Burney CO holds 832 shares of VRTX stock, worth $394,184. This represents 0.01% of its overall portfolio holdings.

Number of Shares

832

Previous 6,498 87.2%

Holding current value

$394,184

Previous $2.64 Million 86.87%

% of portfolio

0.01%

Previous 0.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 22, 2024	SELL	$407.69 - $446.08 $2.31 Million - $2.53 Million	-5,666 Reduced 87.2%	832 $347,000
Q4 2023 Feb 12, 2024	BUY	$343.0 - $410.68 $1.99 Million - $2.39 Million	5,815 Added 851.39%	6,498 $2.64 Million
Q3 2023 Nov 08, 2023	BUY	$338.18 - $362.46 $19,614 - $21,022	58 Added 9.28%	683 $237,000
Q2 2023 Aug 09, 2023	BUY	$314.42 - $351.91 $196,512 - $219,943	625 New	625 $219,000
Q4 2022 Feb 06, 2023	BUY	$285.76 - $321.48 $84,299 - $94,836	295 Added 5.52%	5,639 $1.63 Million

Q3 2022 Nov 15, 2022	BUY	$273.83 - $305.53 $1.22 Million - $1.36 Million	4,440 Added 491.15%	5,344 $1.55 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $21,851 - $27,207	-93 Reduced 9.33%	904 $255,000
Q1 2022 May 09, 2022	BUY	$221.42 - $260.97 $220,755 - $260,187	997 New	997 $260,000
Q1 2021 May 13, 2021	SELL	$207.02 - $241.31 $391,888 - $456,799	-1,893 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$207.01 - $276.09 $27,532 - $36,719	-133 Reduced 6.56%	1,893 $447,000
Q3 2020 Dec 14, 2020	BUY	$255.65 - $303.1 $517,946 - $614,080	2,026 New	2,026 $551,000

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Burney CO, based on Form 13F filings with the SEC.

News

Stay updated on Burney CO with notifications on news.

Account